ST8155AA1 

ST8155AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor. ST8155AA1 induces α-tubulin, histone H3/H4 acetylation via direct enzymatic inhibition. ST8155AA1 recognizes and binds EGFR, undergoes internalization into EGFR-expressing tumor cells. ST8155AA1 inhibits cancer cell proliferation and exerts activity in mouse tumor models. ST8155AA1 can be used for the research of non-small cell lung cancer^[1].

ST8155AA1 specifically binds to EGFR with sub-nanomolar range affinity^[1].
ST8155AA1 is efficiently internalized into EGFR-expressing Capan-1, NCI-H1975, and A549 human tumor cells following target binding^[1].
ST8155AA1 inhibits HDAC activity in NCI-H1975 human lung carcinoma cells, as evidenced by increased acetylation of alpha-tubulin and histones H3 and H4^[1].
ST8155AA1 (6 days) inhibits proliferation of NCI-H1975 and Calu-3 human lung adenocarcinoma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ST8155AA1 (50 mg/kg; i.p.; once every 4 days; 4 doses) demonstrates anti-tumor activity in a mouse NCI-H1975 model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

867.07

C₄₃H₆₂N₈O₉S

2247025-63-2

O=C(O)CCCCCC(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(CSCCCCC[C@H](NC([C@H]2CCC(N2)=O)=O)C(NC3=CC=CC=C3)=O)C=C1)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cini E, et al. Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation. Chem Sci. 2018;9(31):6490-6496. Published 2018 Jul 3.  [Content Brief]